TrialJournal for immunotherapy of cancer2022

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.

Nizar M Tannir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.